What Artio Medical does

Artio Medical is a privately held, development-stage medical device company developing endovascular embolization products for peripheral vascular and neurovascular applications. The company was founded in 2014 as Metactive Medical, rebranded to Artio Medical in February 2020, and is headquartered in Prairie Village, Kansas, with 1-10 employees. Artio's portfolio comprises five in-development devices: Solus Gold (a detachable gold metal implant on a dual catheter delivery system for peripheral vessel embolization), Solus Flex (a polymer balloon with platinum/nitinol coil for tortuous peripheral vessels), Aneura (balloon-plus-coil system for peripheral aneurysms), Endura (balloon-plus-coil system for cerebral aneurysms), and Amplifi (a wearable external blood pump for hemodialysis vein preparation, acquired from Flow Forward Medical in 2020).

The underlying technical thesis across the Solus, Aneura, and Endura platforms is immediate vessel occlusion via solid mechanical barriers rather than clot-dependent mechanisms, paired with detachable balloons intended to cover aneurysm necks and reduce coil prolapse. Solus Gold is described as the first metal implant designed to provide a solid barrier to blood flow. Amplifi, acquired via the stock-for-stock merger with Flow Forward Medical, targets a different but adjacent clinical problem: roughly 35% of US hemodialysis patients are ineligible for arteriovenous fistula (AVF) creation due to small veins, and more than 50% of AVFs fail to mature without additional procedures.

Commercially, Artio is pre-revenue — all products are in development and not available for sale pending regulatory approvals. The company is pursuing 510(k) marketing clearance from the FDA for Solus Gold as its first US launch asset and is building a direct enterprise sales organization targeting hospitals and interventional radiology/vascular surgery departments. The company has raised approximately $74 million in total funding across multiple Series A tranches between 2020 and 2022, led by Nathaniel and Sarah Hagedorn, with additional participation from Accelerate Venture Partners, Kansas Bioscience Authority, Mid-America Angels, Serra Ventures, and the NIH. Revenue mechanics are expected to follow a hardware sales model once regulatory clearances are obtained, with no public pricing disclosed to date.

Name

Artio Medical

Legal name

Artio Medical, Inc.

Website

https://artiomedical.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

1–10 employees

Ownership category

akta.pro rank

Product category

Endovascular Medical Devices

NAICS

Surgical and Medical Instrument Manufacturing (339112), Surgical Appliance and Supplies Manufacturing (339113), Medical Equipment and Supplies Manufacturing (3391)

SIC

Surgical & Medical Instruments & Apparatus (3841), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)

akta.pro primary industry

Thrombectomy, Embolic Protection & Stroke Intervention Devices (HLAHAFAJ)

akta.pro secondary industry

Vascular Access Devices (AV Grafts, Catheters, Fistula Accessories) (HLAHAKAE)

Keywords

• Endovascular embolization devices
• Peripheral vascular devices
• Neurovascular medical devices
• Cerebral aneurysm treatment
• Hemodialysis vascular access

Headquarters

HQ city

Olathe

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Medical Device Sales: Pre-revenue company. Plans to generate revenue through commercial sales of peripheral vascular and neurovascular embolization devices and the Amplifi Vein Dilation System after obtaining regulatory approvals.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels3 records

Core offering

Artio Medical develops endovascular medical devices for the embolization of blood vessels and aneurysms, plus a vein dilation system for hemodialysis patients. Its portfolio includes detachable metal and polymer implants delivered through catheter-based systems for peripheral and neurovascular applications, as well as an external wearable blood pump for arteriovenous fistula (AVF) preparation. All products are currently in development and not yet commercially available for sale pending regulatory clearances.

Product overview

Artio Medical is a medical device company developing a portfolio of embolization devices for peripheral vascular and neurovascular applications. The product portfolio includes: Solus Gold™ (gold metal embolization implant for peripheral vessels), Solus Flex™ (polymer balloon with coil for peripheral vessels), Aneura™ (coils and balloon system for peripheral aneurysms), Endura™ (coils and balloon system for cerebral aneurysms), and Amplifi™ (vein dilation system for hemodialysis patients). All products are currently in development and not available for sale. The company was founded in 2014 as Metactive Medical and rebranded to Artio Medical in February 2020.

Differentiator

Problem solved

Functional benefit

Brands

• Solus Gold: Embolization Device for peripheral vessels - optimized for precision placement and physician ease-of-use with gold metal implant
• Solus Flex
• Aneura
• Endura
• Amplifi

Products and services

• Solus Gold™ Embolization Device A gold metal implant mounted on a dual catheter delivery system designed for precision placement and immediate vessel occlusion in peripheral vessels. Features a detachable gold implant with an independent 2.0 Fr microcatheter and 3.3 Fr delivery catheter; positioned as the first metal implant to provide a solid barrier to blood flow. Target users are interventional radiologists and vascular surgeons treating peripheral vascular disease.
• Solus Flex™ Embolization Device A polymer balloon mounted on a dual catheter delivery system paired with a resilient platinum and nitinol coil designed to anchor, support, resist compression and migration. Built for passage through tortuous vessels and embolization of vessels subject to crush and bend forces. Target users are interventional radiologists and vascular surgeons treating peripheral vascular disease.
• Aneura™ Embolization System A combination of coils and an accessory balloon for peripheral aneurysms, comprising the Aneura Embolization Device (detachable balloon), Aneura Aneurysm Coils, and Aneura Balloon Coils. Designed to cover the aneurysm neck, frame and fill the aneurysm sac, and reduce coil prolapse for immediate peripheral aneurysm occlusion. Target users are interventional radiologists and vascular surgeons treating peripheral aneurysms.
• Endura™ Embolization System A combination of coils and an accessory balloon for cerebral aneurysms, comprising the Endura Embolization Device (detachable balloon), Endura Aneurysm Coils, and Endura Balloon Coils. Designed to cover the aneurysm neck, reduce coil prolapse into the parent artery, and promote endothelialization with a smooth flat surface for immediate cerebral aneurysm occlusion. Target users are neurointerventionalists and interventional neuroradiologists.
• Amplifi™ Vein Dilation System A wearable, external blood pump system designed to stimulate arm vein enlargement in hemodialysis patients using rapid, non-pulsatile blood flow. Used for 7-10 days prior to arteriovenous fistula creation surgery and removed during the procedure to increase AVF eligibility and maturation. Target users are nephrologists, vascular access surgeons, and dialysis centers treating end-stage renal disease patients.

Quantifiable outcome

• Cerebral aneurysms affect about 4% of global population with nearly 500,000 deaths worldwide annually from brain aneurysm rupture
• +2 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

One partnership is on record.

• Flow Forward Medical, Inc.coreOthers · 8 June 2020Artio Medical acquired Flow Forward Medical through a stock-for-stock merger transaction. Flow Forward developed the Arteriovenous Fistula Eligibility (AFE) System for hemodialysis patients, which was renamed the Amplifi Vein Dilation System under Artio. This acquisition expanded Artio's peripheral vascular portfolio with complementary venous dilation technology.

Scale indicators5 records

Recent moves7 records

Market position

Weaknesses4 records

Competitive moat4 records

Customer concentration

• LinkedInlinkedin.com/company/metactive-medical-inc-

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries1 record

Funding overview

Funding rounds9 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Artio Medical